At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 11, 2026 at 17:02 ET
Pacira BioSciences responded to an activist investor, DOMA Perpetual Capital Management, which has nominated three director candidates for election at the 2026 Annual Meeting. The company reaffirmed its strategic focus on the 5x30 growth plan, highlighted progress including 6.2% EXPAREL volume growth, record gross margins, and pipeline advancements, and emphasized ongoing shareholder engagement. No shareholder action is required at this time.
- DOMA Perpetual Capital Management nominated three director candidates for Pacira's 2026 Annual Meeting.
- Pacira reiterated progress on its 5x30 strategy, including 6.2% year-over-year EXPAREL volume growth in 2025 (up from 3.6% in 2024).
- Treated 2.5 million patients in 2025, on track toward 3 million annually by 2030.
- GAAP gross margin reached 79% in 2025 (up from 76% in 2024); non-GAAP gross margin was 81%.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access